MANTLE CELL LYMPHOMA

Poster number

Title

Submitting author

City and Country

144

Current Role of Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Immunotherapeutic and Targeted Therapies. The GETH/GELTAMO Experience.

Antonio Gutierrez

Palma, Spain

145

Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Marginal Zone Lymphoma: primary analysis of a phase 2 trial from LYSA

Charles Herbaux

Montpellier, France

146

Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Final Results From a Phase 2 Study

Michael Wang

Houston, TX, USA

147

Time to second line Bruton tyrosine kinase therapy and age at its initiation are strongly associated with subsequent overall survival in patients with first relapse of mantle cell lymphoma

Diego Villa

Vancouver, Canada

148

Survival following First Relapse in Younger Patients with Mantle Cell Lymphoma

James Gerson

Philadelphia, PA, USA

149

ROLE OF MAINTENANCE RITUXIMAB AFTER FIRST-LINE BENDAMUSTINE + RITUXIMAB OR R-CHOP IN PATIENTS WITH MANTLE CELL LYMPHOMA FROM A LARGE US REAL-WORLD COHORT

Michael Wang

Houston, TX, USA

150

Rituximab in combination with bendamustine or high-dose cytarabine-based induction therapy in transplant-eligible patients with mantle cell lymphoma

Diego Villa

Vancouver, Canada

151

Prediction of relapse by standardized IG-based allel-specific qPCR, ddPCR and amplicon NGS for MRD monitoring in mantle cell lymphoma: a comparative analysis by the EU-MCL network

Christiane Pott

Kiel, Germany

152

High-risk Mantle Cell Lymphoma in the LyMa Trial: a LYSA Study.

Morgane Cheminant

Paris, France

153

Real-World Treatment Patterns and Outcomes of 3455 Previously Untreated Mantle Cell Lymphoma Patients in US Routine Clinical Practice

Anita Kumar

New York, NY, USA